Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Black Diamond Therapeutics reported updated Phase 2 data for silevertinib in frontline EGFR non-classical mutation lung cancer and said feedback from an October 1, 2026 FDA End of Phase 2 meeting supports a pivotal program. Its third-quarter financial results show a wider net loss than a year earlier, and cash, cash equivalents and investments declined to $102.0 million, which the company says funds operations into the second half of 2028.
Q3 2026 net loss was $10.0 million, compared with $8.5 million in Q3 2025; neither quarter had license revenue.
Nine-month 2026 net loss was $28.95 million, versus net income of $37.5 million in the first nine months of 2025, which included $70 million of license revenue.
Cash, cash equivalents and investments were $102.0 million at September 30, 2026, down from $128.7 million at December 31, 2025.
The planned global Phase 3 trial would enroll 300 patients and could start in the second quarter of 2027, with preliminary data anticipated in 2028.
Rafael Holdings furnished an November 2026 investor presentation under Regulation FD, posted on its website from November 9, 2026. The deck restates that the pivotal Phase 3 TransportNPC study for remibetadex missed its primary endpoint, with a 64% slowing of disease progression versus placebo that was not statistically significant (p=0.19), and that a New Drug Application was submitted in October 2026. The filing also cites substantial doubt about the company's ability to continue as a going concern and its need for additional capital.
Primary endpoint: 64% slowing of disease progression versus placebo, difference −0.81 (p=0.19), described as not statistically significant; a prespecified subgroup analysis reached p=0.046.
Serious treatment-emergent adverse events: 35.9% of remibetadex participants versus 16.7% on placebo over 96 weeks.
NDA submitted October 2026; Day 60 FDA filing decision expected December 27, 2026; potential FDA action around mid-2027 if priority review is granted.
Cash balance of $22.1 million as of July 31, 2026; the forward-looking statements cite going concern doubt and need for additional capital.
Zura Bio said its Phase 2 TibuSHIELD study of tibulizumab in moderate-to-severe hidradenitis suppurativa did not meet its primary endpoint at Week 16 at either dose, and key secondary endpoints were also not met. Based on the results, the company is discontinuing development of tibulizumab in HS, while its systemic sclerosis and polymyalgia rheumatica programs continue. The failure removes one indication from the company's lead product candidate.
Primary endpoint (percentage change from baseline in abscess and inflammatory nodule count) not met: 56.0% reduction at 300 mg and 58.1% at 150 mg, versus 52.5% for placebo
HiSCR50 response was 48.0% (300 mg) and 52.7% (150 mg) versus 45.5% for placebo; HiSCR75 was 35.3% and 34.0% versus 28.1%
Trial enrolled 247 participants; both doses were well tolerated per the company, with one death in the 300 mg arm judged unrelated to treatment by the site investigator
As of September 30, 2026, cash and cash equivalents were $187.7 million, expected to fund operations through at least the end of 2028; TibuSURE topline data expected in H1 2027
Encompass Health said its Sea Pines Rehabilitation Hospital in Melbourne, Florida, remains closed indefinitely after torrential rains on Nov. 1-2, 2026 caused flooding and substantial damage. The company reaffirmed its full-year 2026 guidance, which it said excludes closure-related costs and insurance proceeds from non-GAAP measures, but the closure removes a 90-bed facility from its operations while the joint venture evaluates repair or replacement options.
Sea Pines is a 90-bed hospital owned by a joint venture between Encompass Health and Holmes Regional Medical Center, a subsidiary of Health First.
For the first nine months of 2026, Sea Pines had net operating revenue of approximately $44 million and contributed approximately $14 million to Adjusted EBITDA.
Full-year 2026 guidance was reaffirmed: net operating revenue of $6,450 million to $6,500 million, Adjusted EBITDA of $1,395 million to $1,415 million, and adjusted EPS of $6.23 to $6.37.
All patients were evacuated safely, and the joint venture is in discussions with its partner on the path forward for reopening.
Gyrodyne's CEO told shareholders at the November 5, 2026 annual meeting that the preliminary, unaudited net assets in liquidation estimate fell to approximately $10.75 per share as of September 30, 2026, from $12.30 at June 30, 2026. The decline reflects a shift from the B2K Flowerfield sale, which the company now believes may not close, to a potential sale of the same acreage to New York State, for which no definitive agreement exists.
Preliminary net assets in liquidation estimated at approximately $10.75 per share as of September 30, 2026, a decrease of $1.55 per share, or approximately $3.4 million in aggregate
Company is negotiating a potential sale of undeveloped Flowerfield acreage to New York State and a termination of the B2K agreement, but no definitive agreement has been reached with either party
Company believes there is a material risk the B2K transaction will not close by the end of 2028, if at all, due to an unresolved visual easement issue
Employee headcount reduced from four at the end of 2024 to one full-time employee as of October 2, 2026
Icahn Enterprises L.P. furnished an updated November 2026 investor presentation under Regulation FD. For the twelve months ended September 30, 2026, the deck shows a net loss attributable to IEP of $1.04 billion and Adjusted EBITDA attributable to IEP of negative $257 million, with the Investment segment the largest drag. The filing is a presentation rather than a new results release, and it also highlights the August 2026 sale of Pep Boys and a $2.00 annualized distribution.
Net loss attributable to IEP of $1,038 million for the twelve months ended September 30, 2026; Investment segment net loss attributable to IEP of $797 million
Investment Funds recognized Q3 2026 losses on refining hedges of about $653 million, of which $522 million was attributable to IEP
Pep Boys sale closed August 20, 2026, for $700 million, with an estimated pre-tax gain of $215 million
Annualized distribution of $2.00, a 38.76% yield based on the November 2, 2026 closing price of $5.16
Ocean Power Technologies' Audit Committee dismissed Baker Tilly as its independent auditor on October 26, 2026, citing audit fees and costs among other factors, and appointed Carr, Riggs & Ingram for the fiscal year ending April 30, 2027. Baker Tilly's report on the fiscal year ended April 30, 2026 included a going-concern explanatory paragraph, and the company disclosed material weaknesses in its internal controls, which raises concerns for shareholders about its financial reporting. The filing also describes a non-binding letter of intent with Stratum Holdings for a proposed data center demonstration.
Audit Committee dismissed Baker Tilly effective immediately on October 26, 2026, citing audit fees and costs among other factors.
Baker Tilly's audit report for the fiscal year ended April 30, 2026 included an explanatory paragraph on substantial doubt about the company's ability to continue as a going concern.
Company disclosed material weaknesses in internal control over financial reporting, including controls over complex transactions such as revenue recognition and convertible debt, and over inventory data.
Carr, Riggs & Ingram was appointed as independent registered public accounting firm for the fiscal year ending April 30, 2027.
EyePoint reported topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, which did not meet its primary endpoint of statistical non-inferiority in mean change in best-corrected visual acuity versus on-label aflibercept. The company said several key secondary endpoints were met, and it will run additional analyses of LUCIA and the pooled Phase 3 data to assess next steps for wet AMD, while the DME program continues.
LUCIA did not meet its primary endpoint; the presentation shows a mean BCVA change of +2.5 letters for DURAVYU versus +6.1 letters for aflibercept, a difference of -3.7 letters (preliminary data).
LUCIA enrolled 475 patients; DURAVYU achieved a 38% reduction in treatment burden (nominal p-value below 0.0001) and 52% of eyes were supplement-free up to Week 56.
EyePoint will complete additional analyses of LUCIA and the pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.
Pivotal Phase 3 DME topline data are anticipated in the fourth quarter of 2027.
Arrive AI Inc. said its independent auditor, Stephano Slack LLC, resigned effective October 13, 2026, and that the company engaged M&K CPAS, PLLC the same day to review its September 30, 2026 interim statements and audit fiscal 2026. Stephano Slack's prior audit report on fiscal 2025 included a going-concern explanatory paragraph and cited a material weakness in internal controls that was not fully remediated as of June 30, 2026, which matters for shareholders because it signals ongoing financial reporting and financial viability concerns.
Stephano Slack LLC resigned as auditor effective October 13, 2026; the company describes the separation as amicable.
M&K CPAS, PLLC was engaged on October 13, 2026 for the Q3 2026 review and the fiscal 2026 audit.
Fiscal 2025 audit report included a going-concern paragraph on substantial doubt about the company's ability to continue.
A material weakness tied to embedded derivatives and debt accretion led to 10-Q/A restatements filed April 15, 2026, and was not fully remediated as of June 30, 2026.
BK Technologies disclosed that a severe thunderstorm caused a partial roof collapse at its West Melbourne, Florida headquarters and main industrial facility on October 8, 2026, after business hours, with no employees injured. The company expects temporary effects on production of BKR 9000 radios, BKR 9500 production-readiness activities and radio repair services, and it has not yet estimated the impact on its previously announced financial outlook.
Partial roof collapse at West Melbourne, Florida facility on October 8, 2026, during a severe thunderstorm; no employees were injured
Water damage reported in the server room, production area and customer service area; IT systems at the facility were disrupted
Company has started its disaster recovery procedures and an insurance claims process covering business interruption and other losses, subject to policy terms
Company is evaluating the effect on its outlook but cannot yet reasonably estimate magnitude or timing
Profusa dismissed CBIZ CPAs as its independent auditor on October 5, 2026, and engaged WithumSmith+Brown for fiscal 2026. CBIZ's prior audit report for 2025 included a going-concern paragraph and the company disclosed unremediated material weaknesses in internal control, which matters to shareholders because it signals financial reporting and viability concerns.
CBIZ CPAs dismissed on October 5, 2026; its 2025 audit report had no adverse opinion or disclaimer but included a going-concern explanatory paragraph.
Material weaknesses in internal control, including segregation of duties and complex debt and equity accounting, had not been remediated as of June 30, 2026.
WithumSmith+Brown engaged on October 6, 2026, for the fiscal year ending December 31, 2026, following Audit Committee and Board approval on September 30, 2026.
No disagreements with CBIZ were reported; CBIZ's response letter is filed as Exhibit 16.1.
Bolt Biotherapeutics entered into a second amendment to its Redwood City, California lease on October 1, 2026. The company paid the landlord $1.0 million, agreed the landlord may draw the existing $1.5 million letter of credit in full, and accepted an earlier lease expiration date that would require a $4.5 million termination payment upon a financing or other strategic transaction, which could weigh on shareholders' cash and results.
Company paid the landlord $1.0 million on signing the amendment
Landlord may draw the existing $1.5 million letter of credit in its entirety
Lease expiration accelerated to December 31, 2027, or earlier after a Corporate Transaction, with a $4.5 million termination payment due then
Company says ongoing rent and operating expense obligations are not significant; accounting effects are still being evaluated
Aterian dismissed UHY LLP as its independent auditor effective October 2, 2026, and engaged Haskell & White LLP for fiscal 2026. UHY's reports on the 2024 and 2025 financial statements included a going concern warning citing recurring losses, negative operating cash flow and risk of covenant non-compliance, and the company also engaged former CEO Arturo Rodriguez as a consultant.
UHY's reports for fiscal 2024 and 2025 contained a going concern paragraph citing recurring losses, negative operating cash flows and possible failure to meet credit facility covenants.
The filing reports no disagreements or reportable events with UHY during the two fiscal years and the interim period through October 2, 2026.
Rodriguez will be paid $250 per hour, capped at 12 hours per week and a total of $77,000, with services expected through November 20, 2026 and no later than March 31, 2027.
New Fortress Energy said its Fast LNG (FLNG) unit is offline after a mechanical issue with the facility's gas turbine. The company is working with the turbine manufacturer and expects the unit to return to service during the fourth quarter, which would disrupt production until then.
FLNG unit taken offline following a mechanical issue with its gas turbine
Company is working with the turbine manufacturer to restore operation as soon as possible
Company expects the FLNG unit to return to service during the fourth quarter
Filing warns of possible production delays, spot LNG sourcing costs, and counterparty challenges
Rafael Holdings said its Phase 3 TransportNPC trial of Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C did not achieve statistical significance on the primary endpoint, with a 64% slowing of disease progression versus placebo at Week 96 (p=0.19). A prespecified analysis of patients on background miglustat and/or leucine, about 83% of the study population, was statistically significant (p=0.046), and the company said it remains on track to submit an NDA to the FDA in the fourth quarter of 2026.
Primary endpoint missed statistical significance: difference of -0.81 points, 95% CI -2.04 to 0.41, p=0.19
Prespecified subgroup (n=78) on background miglustat and/or leucine showed a 71% slowing of progression, p=0.046
Serious treatment-emergent adverse events were 35.9% with Trappsol Cyclo versus 16.7% with placebo; one severe bilateral deafness event was reported
NDA submission to the FDA remains planned for the fourth quarter of 2026; investor call held September 30 at 8:30 a.m. ET
Aspire-Lakewood Holdings dismissed Turner Stone & Company, LLP as its independent auditor on September 24, 2026, and the Audit Committee engaged CBIZ CPAs P.C. as its new auditor for the fiscal year ending December 31, 2026. Turner's prior report on the 2025 financial statements included a going concern explanatory paragraph, and the company disclosed material weaknesses in internal control over financial reporting.
Turner Stone & Company, LLP dismissed effective September 24, 2026
CBIZ CPAs P.C. engaged as new auditor for fiscal year ending December 31, 2026
Turner's report on 2025 financials included a going concern paragraph on substantial doubt
Company reports no disagreements with Turner and no other reportable events
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.